"Assessing Xolair (Omalizumab) Utilization and Insurance Coverage Challenges in Idiopathic Urticaria: A Retrospective Analysis of Patient Outcomes and Prior Authorization Delays"

A cohort of 233 individuals from a private allergy& immunology practice was used to understand (1) the proportion of patients with urticaria who were prescribed Xolair; (2) the frequency of insurance coverage denials; and (3) the time between prior authorization (PA) submission and approval.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research